Oxford Vacmedix
Oxford Vacmedix is a biotechnology company focused on developing therapeutic agents for cancer treatment based on Recombinant Overlapping Peptides (ROP). Established in 2012 as a spinout from Oxford University, it works on immunotherapy solutions.
- Immunotherapy development
- Personalised cancer vaccines
- Recombinant Overlapping Peptides (ROP)
- Diagnostics for anti-microbial resistance
Locations
Digital Popularity
Social Media
LinkedIn415 Followers
Competitors
SpyBiotech is a clinical stage company that utilises its unique protein superglue technology to develop vaccines against infectious diseases and cancer.
PACE is a pioneering partnership focused on addressing the global threat of antimicrobial resistance (AMR) through funding and supporting early-stage antimicrobial drug and diagnostics projects.
GeneOmics Solutions is dedicated to early diagnosis and treatment through the integration of multi-omics data for precision medicine.
Company Details
Oxford Vacmedix is operated by Oxford Vacmedix UK Limited and is a Active company incorporated on 16 March 2012 with the registered office located in Oxford, Oxfordshire. Oxford Vacmedix UK Limited was registered 13 years ago.
Status
Active
Size
Micro
Directors
11
Age
13 years old
Employees
6
Turnover
Unreported
Total Assets
£810K
Cash in Bank
£248K
Total Liabilities
-£429K
Teams
2
2
2
CEO • Joined Mar 2018
Director • Joined Dec 2012
CEO • Joined Mar 2018
Director • Joined Dec 2012
CEO • Joined Mar 2018
Director • Joined Dec 2012